PL3578201T3 - Metody i kompozycje dla naturalnych komórek cytotoksycznych - Google Patents

Metody i kompozycje dla naturalnych komórek cytotoksycznych

Info

Publication number
PL3578201T3
PL3578201T3 PL19175670.9T PL19175670T PL3578201T3 PL 3578201 T3 PL3578201 T3 PL 3578201T3 PL 19175670 T PL19175670 T PL 19175670T PL 3578201 T3 PL3578201 T3 PL 3578201T3
Authority
PL
Poland
Prior art keywords
compositions
methods
cytotoxic cells
natural cytotoxic
natural
Prior art date
Application number
PL19175670.9T
Other languages
English (en)
Inventor
Alicja COPIK
Vijay Reddy
Jeremiah OYER
Original Assignee
University Of Central Florida Research Foundation Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Central Florida Research Foundation Incorporated filed Critical University Of Central Florida Research Foundation Incorporated
Publication of PL3578201T3 publication Critical patent/PL3578201T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL19175670.9T 2012-06-28 2013-06-28 Metody i kompozycje dla naturalnych komórek cytotoksycznych PL3578201T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261665591P 2012-06-28 2012-06-28

Publications (1)

Publication Number Publication Date
PL3578201T3 true PL3578201T3 (pl) 2023-09-11

Family

ID=49783918

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19175670.9T PL3578201T3 (pl) 2012-06-28 2013-06-28 Metody i kompozycje dla naturalnych komórek cytotoksycznych

Country Status (16)

Country Link
US (5) US9623082B2 (pl)
EP (3) EP4279579A3 (pl)
AU (4) AU2013282353B2 (pl)
CA (1) CA2877968A1 (pl)
DK (1) DK3578201T3 (pl)
ES (1) ES2943932T3 (pl)
FI (1) FI3578201T3 (pl)
HR (1) HRP20230424T1 (pl)
HU (1) HUE061931T2 (pl)
LT (1) LT3578201T (pl)
PL (1) PL3578201T3 (pl)
PT (1) PT3578201T (pl)
RS (1) RS64172B1 (pl)
SG (2) SG11201408697QA (pl)
SI (1) SI3578201T1 (pl)
WO (1) WO2014005072A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
AU2015339447B2 (en) * 2014-10-27 2021-08-12 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109952369B (zh) * 2016-10-05 2024-03-22 弗罗里达中央大学研究基金会 涉及nk细胞和抗pdl1癌症治疗的方法和组合物
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
AU2018227801B2 (en) * 2017-02-28 2024-02-22 Research Institute At Nationwide Children's Hospital PM21 particles to improve bone marrow homing of NK cells
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CA3064897A1 (en) 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
SG11202008008UA (en) * 2018-02-21 2020-09-29 Univ Texas Universal antigen presenting cells and uses thereof
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
CN109627342B (zh) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 应用于nk细胞培养的蛋白质、培养基配方组合及制备方法
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
SG11202107904PA (en) * 2019-01-24 2021-08-30 University Of Central Florida Research Foundation Inc Compositions and methods for stimulating natural killer cells
CN113646008A (zh) * 2019-01-28 2021-11-12 罗德岛大学理事会 pHLIP®肽介导的细胞表面的表位束缚
EP3917528A4 (en) * 2019-01-28 2022-12-28 University of Rhode Island Board of Trustees TARGETED DELIVERY OF POTENT CYTOTOXIC COMPOUNDS WITH PHLIP®
MX2021009785A (es) * 2019-02-14 2021-09-08 Res Institute At Nationwide Children´S Hospital Uso de particulas de membrana plasmatica, liposomas y exosomas para evaluar la potencia de celulas inmunitarias.
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3989984A4 (en) * 2019-06-25 2024-05-22 City of Hope TREATMENT OF PDL1-POSITIVE TUMORS WITH NK CELLS
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021093881A1 (zh) * 2019-11-14 2021-05-20 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
WO2021116913A1 (en) * 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
AU2021205416B2 (en) 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
WO2021188974A1 (en) * 2020-03-20 2021-09-23 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
EP4163367A4 (en) * 2020-06-09 2024-06-26 Samsung Life Public Welfare Foundation GENETICALLY MANIPULATED CELL STRAIN FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
EP4204546A1 (en) 2020-08-31 2023-07-05 City of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
US20240299542A1 (en) 2021-01-05 2024-09-12 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
KR20240036997A (ko) * 2022-09-14 2024-03-21 재단법인 한국마이크로의료로봇연구원 사이토카인 활성 강화된 자연살해세포 유래 엑소좀의 암 치료용 생물학적 조성물 및 이의 용도
CN117987365B (zh) * 2023-12-27 2024-08-06 常州市第一人民医院 一种裂亡前列腺癌细胞囊泡的工程化改造方法及其应用
WO2026050706A1 (en) 2024-08-30 2026-03-05 Aventis Inc. Nk cells having reduced cd38 expression and method for producing
WO2026068686A1 (en) 2024-09-27 2026-04-02 Kiadis Pharma Intellectual Property B.V. Methods of enhancing plasma membrane particle functionality and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
KR100773109B1 (ko) * 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
MXPA03002278A (es) * 2000-09-14 2004-12-03 Beth Israel Hospital Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005070120A2 (en) 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
WO2005124346A1 (en) * 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
JP5525689B2 (ja) * 2004-11-02 2014-06-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 過剰増殖性障害を処置するための組成物および方法
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
US20070122413A1 (en) * 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
EP1973572A2 (en) 2005-12-08 2008-10-01 University of Louisville Research Foundation, Inc. In vivo cell surface engineering
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
WO2010071836A1 (en) 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013175237A1 (en) * 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent

Also Published As

Publication number Publication date
EP3578201A1 (en) 2019-12-11
ES2943932T3 (es) 2023-06-16
EP2866834A1 (en) 2015-05-06
WO2014005072A1 (en) 2014-01-03
US20190117736A1 (en) 2019-04-25
AU2024267081A1 (en) 2024-12-19
US10874715B2 (en) 2020-12-29
LT3578201T (lt) 2023-05-25
HUE061931T2 (hu) 2023-09-28
SI3578201T1 (sl) 2023-06-30
RS64172B1 (sr) 2023-05-31
AU2013282353B2 (en) 2018-10-25
SG10201610915XA (en) 2017-02-27
US20150190471A1 (en) 2015-07-09
EP4279579A3 (en) 2024-02-21
AU2013282353A1 (en) 2015-02-12
US11617781B2 (en) 2023-04-04
US20170319659A1 (en) 2017-11-09
US9623082B2 (en) 2017-04-18
EP3578201B1 (en) 2023-04-19
AU2021202439A1 (en) 2021-05-13
US20200138908A1 (en) 2020-05-07
AU2021202439B2 (en) 2024-09-05
AU2019200525A1 (en) 2019-02-14
US10463715B2 (en) 2019-11-05
EP4279579A2 (en) 2023-11-22
US12280094B2 (en) 2025-04-22
FI3578201T3 (fi) 2023-05-05
AU2019200525B2 (en) 2021-01-21
HRP20230424T1 (hr) 2023-07-07
US20230321191A1 (en) 2023-10-12
EP2866834A4 (en) 2015-12-09
PT3578201T (pt) 2023-05-10
SG11201408697QA (en) 2015-02-27
CA2877968A1 (en) 2014-01-03
DK3578201T3 (da) 2023-05-08
EP2866834B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
IL264271A (en) Methods of generating natural killer cells
PT3578201T (pt) Métodos e composições para células assassinas naturais
PL2884999T3 (pl) Sposób i kompozycje do immunoterapii komórkowej
IL267283A (en) Methods and preparations for producing epicardial cells
IL242273B (en) Methods and compositions for enhancing cd4+ regulatory t cells
SI2978419T1 (sl) Sestavki za izboljšanje viabilnosti celic in postopki njihove uporabe
PL2734049T3 (pl) Kompozycje probiotyczne i sposoby
CL2014003386A1 (es) Métodos y composiciones para producción de biometano
EP3488847C0 (en) SEMIFLUORINATED ALKANE COMPOSITIONS
HRP20181448T1 (hr) Antihelmintski spojevi i sastavi te postupak za njihovu uporabu
EP2850187A4 (en) COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2943591A4 (en) METHOD AND COMPOSITIONS FOR PROFILING SINGLE CELL EXPRESSION
IL229176A0 (en) Preparations of living cells and their uses
EP2758183A4 (en) BIODEGRADABLE COMPOSITIONS AND THEIR USE
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
ZA201406726B (en) Methods and composition related to brown adipose-like cells
GB201200458D0 (en) Methods of preparing cells and compositions
ME03029B (me) Kompozicije koje obuhvataju vortioksetin i donepezil
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
EP2735581A4 (en) COMPOSITION AND POLYMER
BR112013033137A2 (pt) composições e soluções de glicerol
EP2932536A4 (en) COMPOSITIONS AND METHODS FOR ENHANCED SOLAR CELLS
DK2935530T3 (da) Fischer-tropsch-afledte brændstofsammensætninger